<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSES: Satraplatin acts as a potent inhibitor of proliferation in castration-resistant <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, yet the basic and molecular pharmacological mechanisms are still unknown in <z:hpo ids='HP_0000001'>all</z:hpo> types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In an effort to explain the mechanism of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> sensitivity to satraplatin, the cytotoxic effects in a panel of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines was examined with regard to their p53 genotype in comparison with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were chosen to ascertain the mechanism of satraplatin-enhanced cytotoxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Cells were incubated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and satraplatin for 24-72 h, followed by the assessment of cell chemosensitivity with MTS </plain></SENT>
<SENT sid="4" pm="."><plain>Western blot analysis was used to detect the expressions of p53-related molecules </plain></SENT>
<SENT sid="5" pm="."><plain>Flow cytometry was used to monitor cell cycle perturbation while qRT-PCR to detect <z:chebi fb="2" ids="33699">mRNA</z:chebi> and miRNAs activities </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Satraplatin treatment resulted an elevated increase in cell <z:hpo ids='HP_0011420'>death</z:hpo> in vitro compared to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> preceded by an <z:hpo ids='HP_0011009'>acute</z:hpo> arrest at G2/M phase, along with cyclin B1 and p21(waf/cip1) up-regulation </plain></SENT>
<SENT sid="7" pm="."><plain>It also exhibited fourfold higher cellular <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> accumulations compared to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Satraplatin treatment induces p53-related genes and its direct microRNA target of miR-34a independently </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, it potentiates <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via multiple <z:hpo ids='HP_0011420'>death</z:hpo> pathways including the caspase 8 cleavages and Fas protein expression </plain></SENT>
<SENT sid="10" pm="."><plain>The data suggest that the loss of p53 can increase <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> resistance but not satraplatin resistance </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Further molecular biology studies are needed to identify the activity of satraplatin in <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-resistant <z:e sem="disease" ids="C1516211" disease_type="Experimental Model of Disease" abbrv="">cancer models</z:e> and to determine whether this orally administered <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> analogue has synergistic effects in combination with other chemotherapy agents </plain></SENT>
</text></document>